

AVI BIOPHARMA, INC.
(A Development-Stage Company)
(unaudited)
(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	<u>2009</u>	<u>2008</u>	<u>2009</u>	<u>2008</u>
Revenues from license fees, grants and research contracts	\$ 6,349	\$ 5,171	\$ 12,444	\$ 15,778
Operating expenses:				
Research and development	7,473	7,680	17,771	22,261
General and administrative	1,800	3,429	6,226	8,165
Acquired in-process research and development	-	-	-	9,916
Operating loss	<u>(2,924)</u>	<u>(5,938)</u>	<u>(11,553)</u>	<u>(24,564)</u>
Other income (loss):				
Interest (expense) income and other, net	(127)	60	(142)	308
(Increase) decrease on warrant valuation	<u>(5,039)</u>	<u>(169)</u>	<u>(16,989)</u>	<u>1,444</u>
Net loss	<u>\$ (8,090)</u>	<u>\$ (6,047)</u>	<u>\$ (28,684)</u>	<u>\$ (22,812)</u>
Net loss per share— basic and diluted	<u>\$ (0.08)</u>	<u>\$ (0.08)</u>	<u>\$ (0.33)</u>	<u>\$ (0.33)</u>
Shares used in per share calculations	<u>95,261</u>	<u>71,151</u>	<u>87,493</u>	<u>69,160</u>

BALANCE SHEET HIGHLIGHTS
(unaudited)
(in thousands)

	September 30, 2009	December 31, 2008
Cash, cash equivalents and short-term securities	\$ 50,437	\$ 11,474
Total current assets	56,947	17,044
Total assets	65,123	25,536
Total current liabilities	43,059	7,288
Total shareholders' equity	\$ 19,504	\$ 15,732